Some patients begin systemic menopause hormone therapy and notice fewer hot flashes and better sleep, yet vaginal dryness, burning or painful intercourse remain. That experience is not necessarily evidence that the systemic treatment has failed. Genitourinary syndrome of menopause (GSM) involves changes in vulvovaginal and lower urinary tract tissues, and these symptoms may need a separate evaluation and treatment plan.
Why treating hot flashes may not resolve vaginal symptoms
Systemic estrogen therapy can relieve vasomotor symptoms and may improve some genitourinary symptoms. But tissue symptoms do not always respond fully. Vaginal dryness, irritation, discomfort with penetration and some urinary complaints can persist even when systemic symptoms improve. Increasing a systemic hormone dose solely to treat local symptoms is not automatically the best next step.
The 2025 AUA/SUFU/AUGS guideline emphasizes diagnosing GSM from symptoms, with or without physical findings, after considering alternative or coexisting causes. It also identifies local low-dose vaginal estrogen as having the most robust evidence base among evaluated options. Treatment should still be selected through shared decision-making.
Confirm the cause before changing hormones
Persistent burning or pain may reflect GSM, but not every symptom after menopause is caused by low estrogen. Depending on the history and examination, clinicians may consider vulvovaginal infection, contact dermatitis from soaps or lubricants, vulvar dermatoses, pelvic-floor muscle dysfunction, urinary tract infection or other gynecologic conditions. Persistent bleeding, a new lesion or unexplained severe pain requires prompt assessment rather than an empiric dose adjustment.
A focused history asks when symptoms started, whether discomfort is at the opening or deeper, whether symptoms occur outside intercourse, and whether urinary urgency, dysuria or recurrent infections are present. Medication use, sexual history and personal cancer history can influence the workup and treatment discussion.
What options can be considered alongside systemic therapy?
Moisturizers and lubricants: Regular vaginal moisturizers may help ongoing dryness, while lubricants can reduce friction during sexual activity. They do not reverse all tissue changes, and products can themselves cause irritation in sensitive patients.
Local low-dose vaginal estrogen: A clinician may consider local therapy for persistent GSM even when a patient is already using systemic hormones. Preparations, application schedules and contraindication discussions vary. Patients should not add prescription treatment without reviewing their medical history and current regimen.
Other prescription choices: Vaginal prasterone (DHEA) and oral ospemifene are options for selected symptoms and patients, but they have distinct indications, precautions and prescribing considerations. They should not be treated as interchangeable with local estrogen or with one another.
Pelvic-floor care: When muscle tenderness or involuntary tightening contributes to painful intercourse, pelvic-floor physical therapy may be appropriate alongside treatment of tissue symptoms. A referral can be more helpful than escalating hormone doses alone.
What about a history of breast cancer or blood clots?
These situations call for individualized discussion rather than blanket assurances. The route and dose of hormone exposure matter, but so do the cancer type, treatments, recurrence risk and patient preferences. Patients with a history of estrogen-dependent cancer should coordinate decisions with the relevant oncology team. Systemic hormone therapy and local therapies have different risk considerations; the choice should not be made from a blog alone.
How to prepare for a follow-up appointment
Bring a list of current hormone formulations and doses, the timing of symptom changes, all vaginal products used and any bleeding or urinary symptoms. Describe which problem matters most: daily dryness, intercourse pain, recurrent infections or another concern. That allows the clinician to select the appropriate examination, testing and treatment discussion rather than assuming every symptom needs more systemic estrogen.
Our GSM and vaginal atrophy treatment page explains the clinical evaluation, while our menopause treatment page covers broader menopause management. This article addresses the specific question of persistent local symptoms during systemic treatment rather than repeating those service pages.
Bottom line
Persistent vaginal or urinary symptoms deserve a diagnosis, not an automatic systemic dose increase. GSM often benefits from its own treatment plan, and coexisting causes of discomfort should not be missed.
Medical references
- Kaufman et al., AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause (Journal of Urology, September 2025).
- American Urological Association guideline overview (2025).
For educational purposes only. Evaluation and treatment must be individualized by a licensed clinician.
